SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- J INTS BIO announced research findings on its innovative brain tumor treatment, 'JIN-001,' developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA. MD Anderson is a globally renowned cancer research institution, and J INTS BIO has partnered with it since 2021 to advance this groundbreaking therapy.
JIN-001: Aiming to Revolutionize Brain Tumor Treatment
'JIN-001' targets glioblastoma (GBM) cells by significantly enhancing the efficacy of radiation therapy and chemotherapy. As a selective inhibitor of HSP90 (Heat Shock Protein 90), its primary advantage lies in its ability to cross the blood-brain barrier (BBB), which typically hinders therapeutic agents from reaching the brain. While the BBB serves as a protective mechanism for the brain, it also presents a major obstacle for drug delivery. JIN-001 overcomes this limitation, directly attacking brain tumors and addressing the low permeability issue of existing drugs.
The study also highlighted that JIN-001 demonstrated promising results when combined with standard therapies such as Radiation Therapy and Temozolomide, effectively suppressing tumor cell growth and inducing apoptosis (programmed cell death).
JIN-001: Pioneering Future Clinical Developments
Based on these promising findings, J INTS BIO plans to accelerate preclinical trials for JIN-001. The company intends to incorporate CRISPR gene-editing technology to identify the functional roles of specific genetic factors in treatment resistance, paving the way for precision medicine strategies. CRISPR-based techniques allow targeted modulation of gene expression, helping to predict and better understand tumor responses.
J INTS BIO is also advancing plans to commercialize JIN-001 through partnerships with global pharmaceutical companies, aiming to bring faster and more effective treatments to brain tumor patients. Furthermore, the potential applications of JIN-001 are being explored in treating a wide range of cancers beyond brain tumors, providing new hope for cancer patients worldwide.
JIN-001 represents a groundbreaking innovation that transcends the limitations of existing therapies, offering new treatment opportunities and hope for improved survival and quality of life for brain tumor patients.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy
OTTAWA, ON, May 29, 2026 /PRNewswire/ -- Gastops, a Canadian leader in intelligent condition monitoring and maintenance solutions, today announced it has been awarded a contract for FluidSIGHT™ under Canada's Innovation for Defence Excellence and Security (IDEaS) program as a Test Drives participant in the All Systems Go! challenge.
Test Drives enable the Department of National Defence (DND) and the Canadian Armed Forces (CAF) to evaluate innovative technologies in realistic operating environments to assess their potential to address future defence capability needs. As part of this effort, Gastops will further adapt and demonstrate its FluidSIGHT technology in support of advanced health and usage monitoring applications onboard military land vehicles, helping inform future capability decisions.
FluidSIGHT is a real-time oil condition, contamination, and wear monitoring system that provides continuous insight into the health of lubricated systems directly at the asset. FluidSIGHT allows operators to transition from periodic oil sampling to continuous, real-time condition awareness.
The IDEaS program has played a key role in advancing FluidSIGHT's technical maturity. Through participation in an IDEaS Competitive Projects challenge, Gastops has progressed FluidSIGHT from an early proof‑of‑concept to a deployable, testable system suitable for evaluation. The Test Drives phase represents a critical step in validating the technology's performance, integration readiness, and operational relevance alongside DND and CAF stakeholders.
"Being selected for IDEaS Test Drives reflects both the technical maturity of FluidSIGHT and its alignment with Canada's defence innovation priorities," said Shaun Horning, President and CEO at Gastops. "The IDEaS program has allowed us to systematically mature FluidSIGHT from concept to a product that can now be evaluated in a brand-new environment, military land vehicles, helping demonstrate how real-time oil condition awareness can improve equipment availability, safety, and maintenance decision‑making."
Gastops brings decades of experience delivering diagnostics, prognostics, and condition‑based maintenance solutions for mission‑critical platforms across aerospace, defence, marine, energy, and industrial sectors. The IDEaS Test Drives project builds on this foundation and supports Canada's objective to accelerate the adoption of innovative, Canadian-developed technologies in defence and security applications.
About Gastops
Gastops is the world's leading provider of intelligent condition monitoring solutions used in Aerospace, Defence, Energy, and Industrial applications to optimize the availability, performance, and safety of critical assets. We offer peace of mind to our customers with innovative online monitoring sensors, at-line analysis, complex modeling and simulation, world-class laboratory testing, engineering, design, and MRO services that predict performance to enable proactive operating decisions. We have been providing powerful insights into the condition of critical equipment since 1979. Gastops is the intelligence inside what moves you.
www.gastops.com
Media Contacts: media@gastops.com, +1 (613) 744-3530
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Gastops FluidSIGHT™ Awarded IDEaS Test Drives Contract Under Canada's All Systems Go! Challenge
